Stockscreener 앱 받기
20.01
0.50%
-0.10
전일 마감가:
$20.11
열려 있는:
$20.06
하루 거래량:
259.52K
Relative Volume:
0.57
시가총액:
$1.01B
수익:
$62.02M
순이익/손실:
$-45.65M
주가수익비율:
-21.75
EPS:
-0.92
순현금흐름:
$-9.60M
1주 성능:
+5.09%
1개월 성능:
+14.15%
6개월 성능:
+71.76%
1년 성능:
+137.09%
1일 변동 폭
$19.63
$20.31
1주일 범위
$18.41
$20.79
52주 변동 폭
$7.90
$20.79
Theravance Biopharma Inc Stock (TBPH) Company Profile
명칭
Theravance Biopharma Inc
전화
650-808-6000
주소
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
TBPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
20.01 | 1.02B | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 개시 | Oppenheimer | Outperform |
| 2025-09-12 | 개시 | B. Riley Securities | Buy |
| 2024-08-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | 개시 | BTIG Research | Buy |
| 2024-01-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-15 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-08-25 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | 개시 | JP Morgan | Overweight |
| 2020-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-05-13 | 개시 | Cowen | Outperform |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-06 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | 개시 | H.C. Wainwright | Buy |
| 2018-03-29 | 재개 | Piper Jaffray | Overweight |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-05-11 | 재확인 | Needham | Buy |
| 2016-12-21 | 개시 | Needham | Buy |
| 2016-11-03 | 개시 | Piper Jaffray | Overweight |
| 2016-10-12 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | 개시 | Guggenheim | Buy |
| 2016-06-20 | 재확인 | Leerink Partners | Outperform |
| 2016-05-12 | 개시 | Leerink Partners | Outperform |
| 2016-05-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
모두보기
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
Why Theravance Biopharma (TBPH) is a Top Growth Stock for the Long-Term - Yahoo Finance
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Theravance Biopharma stock hits 52-week high at 20.69 USD By Investing.com - Investing.com Nigeria
Theravance Biopharma stock hits 52-week high at 20.69 USD - Investing.com
Trading the Move, Not the Narrative: (TBPH) Edition - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Sets New 12-Month HighWhat's Next? - MarketBeat
Theravance Biopharma CEO earns 2026 Honorable Mentor title - Traders Union
Theravance Biopharma, Inc. Announces Upcoming Phase 3 Data for Ampreloxetine - TradingView — Track All Markets
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Unpacking A 40% Potential Upside - DirectorsTalk Interviews
What valuation ratios show for Theravance Biopharma Inc. (0TB) stockJuly 2025 Technicals & Reliable Entry Point Alerts - Улправда
Chart Watch: What valuation ratios show for Theravance Biopharma Inc. (0TB) stockWeekly Trend Recap & Smart Investment Allocation Tips - Улправда
Will Theravance Biopharma Inc. stock deliver better than expected guidanceMarket Activity Summary & Verified Momentum Stock Ideas - Улправда
Published on: 2026-01-08 18:37:29 - Улправда
Why Theravance Biopharma (TBPH) is a Top Momentum Stock for the Long-Term - Yahoo Finance
mF International, Theravance Biopharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World
(TBPH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Theravance Biopharma (NASDAQ:TBPH) Lowered to Buy Rating by Wall Street Zen - MarketBeat
Portfolio Update: Why Theravance Biopharma Inc 0TB stock stays resilient2025 Short Interest & Daily Entry Point Alerts - moha.gov.vn
Can Theravance Biopharma's Ampreloxetine Fill The Gap In MSA-Related NOH Therapy? - RTTNews
Market Overview: Is Theravance Biopharma Inc stock trading near support levels2025 Macro Impact & Weekly Return Optimization Plans - Bộ Nội Vụ
What drives Theravance Biopharma Inc stock priceMarket Insider Reports & Build Your Portfolio With Our Free Stock Scanner - earlytimes.in
Inspire Investing LLC Purchases New Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock - sharewise.com
(TBPH) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Wall Street Analysts Believe Theravance Bio (TBPH) Could Rally 42.15%: Here's is How to Trade - Finviz
Assenagon Asset Management S.A. Boosts Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
With Theravance Biopharma Stock Surging, Have You Considered The Downside? - Trefis
Why Theravance Biopharma Inc. stock could outperform in 2025Portfolio Return Report & Verified Entry Point Detection - Улправда
How Theravance Biopharma Inc. stock reacts to global recession fears2025 Market WrapUp & AI Driven Stock Movement Reports - Улправда
How Theravance Biopharma Inc. stock reacts to Fed rate cuts2025 Major Catalysts & Real-Time Volume Triggers - Улправда
Will Theravance Biopharma Inc. stock outperform Dow Jones indexMarket Movement Recap & Weekly Stock Breakout Alerts - Улправда
Is Theravance Biopharma Inc. stock trading near support levelsWeekly Market Outlook & Free Expert Verified Stock Movement Alerts - DonanımHaber
Will Theravance Biopharma Inc. stock attract ESG investorsMarket Growth Report & Free Community Consensus Stock Picks - DonanımHaber
Is Theravance Biopharma Inc. (0TB) stock a buy before new product rolloutJuly 2025 Earnings & Short-Term Swing Trade Alerts - DonanımHaber
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Unveiling a 46.94% Potential Upside for Investors - DirectorsTalk Interviews
Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System AtrophySlideshow (NASDAQ:TBPH) 2025-12-15 - Seeking Alpha
Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Wall Street Zen - MarketBeat
History Review: How Theravance Biopharma Inc. stock reacts to global recession fearsRate Hike & Scalable Portfolio Growth Methods - moha.gov.vn
Why The Narrative Around Theravance Biopharma Is Shifting After Trelegy Monetization And Strategic Review - Yahoo Finance
Camber Capital Management LP Trims Stock Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
How (TBPH) Movements Inform Risk Allocation Models - Stock Traders Daily
Hsbc Holdings PLC Takes Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? - sharewise.com
Theravance Biopharma initiated with an Outperform at Oppenheimer - MSN
Theravance Biopharma (TBPH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy? - sharewise.com
Theravance Biopharma schedules 2026 annual meeting and hosts investor event By Investing.com - Investing.com Canada
Theravance Biopharma Inc (TBPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):